Streptococcus pneumoniae: Description of the Pathogen, Disease Epidemiology, Treatment, and Prevention
Article first published online: 16 JAN 2012
2005 Pharmacotherapy Publications Inc.
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Volume 25, Issue 9, pages 1193–1212, September 2005
How to Cite
Bridy-Pappas, A. E., Margolis, M. B., Center, K. J. and Isaacman, D. J. (2005), Streptococcus pneumoniae: Description of the Pathogen, Disease Epidemiology, Treatment, and Prevention. Pharmacotherapy, 25: 1193–1212. doi: 10.1592/phco.2005.25.9.1193
- Issue published online: 16 JAN 2012
- Article first published online: 16 JAN 2012
- Streptococcus pneumoniae;
- pneumococcal disease;
- pneumococcal polysaccharide vaccine;
- pneumococcal conjugate vaccine
Streptococcus pneumoniae causes significant morbidity and mortality. Children younger than 2 years and individuals older than 65 years experience the highest rates of pneumococcal disease. Efforts to treat pneumococcal disease have been complicated by increasing resistance to antimicrobials. Prevention efforts have included the pneumococcal polysaccharide vaccines and the pneumococcal conjugate vaccines, with use of these vaccines targeted to those at highest risk for disease. Information and background on S. pneumoniae and pneumococcal disease are provided. Vaccines targeted at this pathogen are reviewed, and the clinical trials that evaluated their safety, efficacy, and effectiveness are summarized. Also provided are recommendations for use of these vaccines.